China Antifungal Drugs Market Size & Outlook, 2023-2030
China antifungal drugs market, 2018-2030 (US$M)
Related Markets
China antifungal drugs market highlights
- The China antifungal drugs market generated a revenue of USD 871.7 million in 2023 and is expected to reach USD 1,381.0 million by 2030.
- The China market is expected to grow at a CAGR of 6.8% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 871.7 million |
| Market revenue in 2030 | USD 1,381.0 million |
| Growth rate | 6.8% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, China accounted for 5.5% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,381.0 million by 2030.
Azoles was the largest segment with a revenue share of 47.65% in 2023. Horizon Databook has segmented the China antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
Players are showing an increased interest in China due to the wide target population. For instance, a review of Pfizer-Basilea’s novel antifungal agent was accepted in China in August 2020. This was expected to provide a new treatment option to patients in the country.
In March 2021, New Drug Application was filed to NMPA by Tianjin Institute of Pharmaceutical Research and HUYABIO International for their antifungal drug candidate Jublia for onychomycosis. Companies are signing licensing agreements to enter the lucrative market.
For instance, Hansoh Pharma and SCYNEXIS signed an agreement, which allows Hansoh Pharma to accelerate commercialization and access to the drug in China.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China antifungal drugs market size, by drug class, 2018-2030 (US$M)
China Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
